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Abstract
Background: Preterm infants are highly susceptible to lung injury. While both chorioamnionitis and
antenatal steroids induce lung maturation, chorioamnionitis is also associated with adverse lung
development. We investigated the ability of bronchoalveolar lavage fluid (BALF) from ventilated preterm
infants to restore alveolar epithelial integrity after injury in vitro, depending on whether or not they were
exposed to chorioamnionitis or antenatal steroids. For this purpose, a translational model for alveolar
epithelial repair was developed and characterised.
Methods: BALF was added to mechanically wounded monolayers of A549 cells. Wound closure was
quantified over time and compared between preterm infants (gestational age < 32 wks) exposed or not
exposed to chorioamnionitis and antenatal steroids (≥ 1 dose). Furthermore, keratinocyte growth factor
(KGF) and vascular endothelial growth factor (VEGF) were quantified in BALF, and their ability to induce
alveolar epithelial repair was evaluated in the model.
Results: On day 0/1, BALF from infants exposed to antenatal steroids significantly increased epithelial
repair (40.3 ± 35.5 vs. -6.3 ± 75.0% above control/mg protein), while chorioamnionitis decreased wound-
healing capacity of BALF (-2.9 ± 87.1 vs. 40.2 ± 36.9% above control/mg protein). BALF from patients with
chorioamnionitis contained less KGF (11 (0-27) vs. 0 (0-4) pg/ml) and less detectable VEGF (66 vs. 95%)
on day 0. BALF levels of VEGF and KGF correlated with its ability to induce wound repair. Moreover, KGF
stimulated epithelial repair dose-dependently, although the low levels in BALF suggest KGF is not a major
modulator of BALF-induced wound repair. VEGF also stimulated alveolar epithelial repair, an effect that
was blocked by addition of soluble VEGF receptor-1 (sVEGFr1/Flt-1). However, BALF-induced wound
repair was not significantly affected by addition of sVEGFr1.
Conclusion: Antenatal steroids improve the ability of BALF derived from preterm infants to stimulate
alveolar epithelial repair in vitro. Conversely, chorioamnionitis is associated with decreased wound-healing
capacity of BALF. A definite role for KGF and VEGF in either process could not be established. Decreased
ability to induce alveolar epithelial repair after injury may contribute to the association between
chorioamnionitis and adverse lung development in mechanically ventilated preterm infants.
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Background
Antenatal steroid administration and intrauterine inflam-
mation are two important factors capable of promoting
lung maturation before birth. Maternal administration of
corticosteroids in case of anticipated preterm delivery
enhances structural lung maturation and stimulates sur-
factant secretion in the fetus, and has become standard of
care in current obstetric practice [1,2]. Intrauterine inflam-
mation, represented histopathologically by chorioamnio-
nitis, stimulates lung maturation and decreases the
incidence of the respiratory distress syndrome (RDS) [3-
6].
Although both chorioamnionitis and antenatal steroids
induce lung maturation, a single course of antenatal ster-
oids does not seem to affect longer term lung develop-
ment while chorioamnionitis does [1,3,4]. Several studies
have shown an association between chorioamnionitis
and subsequent development of chronic lung disease of
prematurity (bronchopulmonary dysplasia; BPD) [3].
Experimental chorioamnionitis in animals, besides induc-
ing lung maturation, also results in a pathological picture
of alveolar simplification similar to that of BPD currently
seen in preterm infants [4]. This suggests that, although
the short term effect appears similar, both entities induce
different responses affecting subsequent lung develop-
ment. The notion that antenatal steroid administration
further reduces RDS incidence in preterm infants exposed
to intrauterine inflammation, also suggests that both
processes exert their effects at least partially through dis-
tinct mechanisms [3].
The mechanisms by which the differential effects of ante-
natal exposure to steroids and inflammation induce lung
maturation and affect lung development are incompletely
understood. Different effects of both antecedents on pul-
monary growth factor expression have been demonstrated
[2,4,7]. However, lung development is a dynamic, com-
plex and tightly regulated process involving multiple cell
types, effector molecules and interactions. By quantifying
biological activity of human lung-derived specimens, all
potential modulators present are allowed to conduct their
effects. An available model for this purpose is the epithe-
lial wound healing model. After induction of a mechani-
cal defect in cultured epithelial cells, the effect of a
modulator on the ability of the epithelium to restore its
integrity is evaluated. A translational approach can be
made by evaluating the effect of human lung-derived fluid
obtained in vivo on alveolar wound healing capacity in
vitro [8]. Using this approach relevant differences between
distinct patient groups have been reported [9,10].
This model has not been applied in neonatal pulmonary
medicine, while it offers comparison of biological activity
of lung-derived fluid between patients that were or were
not exposed to either antenatal steroids or chorioamnio-
nitis to evaluate their effects on the ability to restore alve-
olar epithelial injury. This is of particular interest for
chorioamnionitis, since the relationship between chorio-
amnionitis and adverse lung development has been
shown to be predominantly modulated by postnatal
injury. Clinical data suggest that chorioamnionitis in itself
is not a risk factor for adverse lung development and may
actually even be protective, while subsequent postnatal
exposure to either sepsis, mechanical ventilation or both
highly increases BPD risk [11-14].
We hypothesised that chorioamnionitis reduces the abil-
ity of lung-derived fluid to restore alveolar epithelial
integrity after injury, while antenatal steroids would have
a stimulatory effect. To test this hypothesis, we developed
a translational in vivo-in vitro model for alveolar epithelial
repair. By collecting bronchoalveolar lavage fluid (BALF)
at consecutive postnatal time points, we evaluated the
time-dependent postnatal effect of both antenatal modu-
lators on BALF biological activity. We further investigated
a potential underlying role of two growth factors in the
BALF-modulated repair process. Vascular endothelial
growth factor (VEGF) is invaluable for normal lung devel-
opment and is decreased in lung-derived fluid from
infants developing BPD [15-18], and in sheep lungs after
experimental chorioamnionitis [7]. Keratinocyte growth
factor (KGF) is a potent stimulant of alveolar repair after
lung injury [19-25] and high KGF in tracheal aspirate fluid
(TAF) has been associated with absence of BPD [26].
Importantly, both growth factors have been shown to
enhance in vitro alveolar epithelial wound healing [27-
29].
Methods
Patient characteristics and enrolment
Patients were eligible for the study when born before 32
weeks gestational age and ventilated for RDS. Patients
were enrolled in the NICUs in the University Hospitals of
Maastricht and Leuven. The Medical Ethical Committees
of both hospitals approved the study and written parental
consent was obtained. Chorioamnionitis was diagnosed
histologically when >10 neutrophils per high-power field
were present in the chorion or amnion. Steroids were
administered to the mother in case of anticipated preterm
delivery by giving two intramuscular doses of betametha-
sone acetate 12 mg 24 hrs apart.
BALF collection and processing
BALF was performed at postnatal days 0-1, 3-4, and 7
according to a standard procedure. After turning the
infant's head to the left, a 6 French suction catheter was
inserted through a side port of the Trachcare® closed suc-
tioning system until slight resistance was felt. Then, one
ml per kg birth weight of sterile isotonic saline solutionRespiratory Research 2009, 10:116 http://respiratory-research.com/content/10/1/116
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was gently infused into the lung. After five seconds, suc-
tioning was performed while slowly retracting the cathe-
ter. The procedure was repeated once after which the
collected fluid was pooled and placed on ice. After centrif-
ugation for 10 minutes at 4°C and 300 × g, the superna-
tant was collected, aliquoted and stored at -80°C until
analysis.
In vitro alveolar epithelial wound healing assay
A549 cells (Sigma-Aldrich, St. Louis, MO, USA) were
seeded in 24-well plates (BD, Franklin Lakes NJ, USA;
approximately 200.000 cells per well) and grown to con-
fluence at 37°C and a 5% CO2-95% air atmosphere in
RPMI 1640 medium (Dutch modification; Invitrogen,
Carslbad CA, USA) supplied with 10% (v/v) fetal bovine
serum (FBS; Greiner Bio-One, Kremsmünster, Austria),
200  μM L-glutamine (L-glut; Invitrogen, Carslbad CA,
USA) and 10 U penicillin + 10 μg streptomycin per ml (P/
S; Invitrogen, Carslbad CA, USA). A black grid printed on
a plastic sheet was attached to the bottom of each plate,
positioning a 2 × 2 mm square underneath the centre of
each well. Between the lines of each square a rectangular
wound was created by gently scratching the monolayer
with a sterile 1 ml pipette tip. By visualisation, scratches of
poor quality were excluded from further analysis before
start of the experiment. After wounding, each well was
washed with 1 ml of phosphate-buffered saline (PBS (pH
7.4); Invitrogen, Carslbad CA, USA) to remove cellular
debris.
For model validation experiments, effects of FBS and albu-
min on wound healing were evaluated by adding various
concentrations of FBS to RPMI 1640 medium + L-glut + P/
S or human serum albumin (A1887, Sigma-Aldrich, St.
Louis MO, USA) to control medium (RPMI 1640 + 0.1%
(v/v) FBS + L-glut + P/S), using 300 μl medium per well.
Various concentrations of BALF diluted in control
medium were added to wounded monolayers, using 300
μl medium per well, to evaluate the effect of BALF dilution
on wound healing. For this purpose, BALF was obtained
from a term newborn ventilated for non-pulmonary rea-
sons.
Effect of BALF, KGF and VEGF on in vitro alveolar 
epithelial wound healing
For BALF experiments, BALF was diluted 1:10 in control
medium and each well was supplied with 300 μl of this
mixture from one BALF specimen after wounding. Con-
trol wells were supplied with isotonic saline 1:10 in con-
trol medium. All experiments were performed in triplicate
and each 24-well plate contained three controls. Moreo-
ver, each plate included one positive control containing
10% (v/v) FBS. In additional experiments, various con-
centrations of human KGF (R&D systems, Minneapolis
MN, USA) diluted in control medium were added to
wounded monolayers in 24-well plates. VEGF (10 pg/ml;
R&D systems, Minneapolis MN, USA), soluble VEGF-
receptor 1 (sVEGFr1/Flt1; R&D systems, Minneapolis MN,
USA) (6 ng/ml) and BALF (1:10 (v/v)) diluted in control
medium were added in distinct experiments, both solitary
and combined, to evaluate their effects on alveolar epithe-
lial wound repair. For this purpose BALF from several
patients was pooled to obtain a large and uniform sample.
Each plate contained three controls and quadruplicates
for each growth factor/receptor concentration.
Assessment of wound healing
Using a Leica DC 300 F camera coupled to a Leica MZ FL
III stereomicroscope, each wound was photographed at a
magnification of 3.15× directly after scratching (t = 0) and
at subsequent time points (6 and 24 hours for BALF exper-
iments). Each well was repeatedly photographed within
the central square of the grid to ensure wound surface
measurements were performed at a fixed position.
The wounded surface was quantified by tracing the
wound edge and calculating the denuded surface area
using Image J software. The assessor was blinded for the
experimental condition of the photograph. Wound heal-
ing was assessed by subtracting the wound area at a given
time point from the wound area at time point zero and
expressed as the percentage of wound healing of each
BALF specimen above the wound healing of the control
wells (containing 0.1% FBS (v/v)) on the same culture
plate.
Quantification of total protein, KGF, VEGF, sVEGFr1, and 
M30
Total protein in BALF was quantified using the NanoOr-
ange® protein quantitation kit (Molecular Probes, Eugene,
OR, USA) according to the manufacturer's instructions.
KGF, VEGF and sVEGFr1 in BALF were quantified by
ELISA (R&D systems, Minneapolis MN) according to the
manufacturer's instructions, in half-area 96-well ELISA
plates (Greiner Bio-One, Kremsmünster, Austria). To
assess the effect of BALF on induction of apoptosis in
A549 cells, M30 (CK18Asp396-NE; a soluble marker of
epithelial cell apoptosis) was quantified in the cell culture
supernatant at the end of the wound healing experiment
(t = 24) using ELISA (Peviva AB, Bromma, Sweden). For
this purpose, triplicates from the culture experiments were
pooled to represent a single patient sample.
Statistics
Continuous data are expressed as mean ± standard devia-
tion if normally distributed, and median plus interquar-
tile range otherwise. Differences between groups were
tested using student t-test and ANOVA with post-hoc Bon-
ferroni correction for comparison of two or three groups,
respectively. Mann-Whitney U test was used for compari-Respiratory Research 2009, 10:116 http://respiratory-research.com/content/10/1/116
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son of non-parametric data and dichotomous variables
were tested using χ2-test. Correlations were determined
using Pearson's correlation coefficient. A test result of p <
0.05 was considered significant (two-tailed). All analyses
were performed using SPSS 15.0 software.
Results
FBS stimulates in vitro alveolar epithelial wound healing
The effect on wound healing of addition of increasing FBS
concentrations to culture medium was evaluated in order
to validate the model (Figure 1A). Addition of FBS con-
centration-dependently stimulated wound closure. A
large number of cells detached from the culture plate dur-
ing incubation without FBS over 24 hours, while cell
attachment was conserved and partial wound closure
occurred during incubation in 0.1% FBS. Thus, this con-
centration was used as the optimal concentration to pre-
serve cell viability and determine the effect of subsequent
addition of BALF.
Wound closure rate
To evaluate wound closure rate, wounded monolayers
were incubated in control medium (0.1% FBS (v/v)) and
positive control medium (10% FBS (v/v)) with serial pho-
tographs taken over a 24-hour period (Figure 1B). In con-
trol medium, wound closure rate decreased over time,
stabilising between four and six hours of incubation. A
more gradual decrease was observed during incubation
with positive control medium.
Characterisation of the alveolar epithelial wound repair model Figure 1
Characterisation of the alveolar epithelial wound repair model. A. Effect of addition of various concentrations of fetal 
bovine serum (FBS) to culture medium on in vitro alveolar epithelial wound healing (A; t = 24 hours). Bars represent mean 
wound closure + SEM (number of pixels ×1000) of triplicate experiments (*p < 0.05; ***p < 0.001 vs. control). B. Differences 
in wound closure rate over time between incubation in control medium (0.1% FBS) and positive control medium (10% FBS). 
Points represent mean wound closure rate + SEM of triplicate experiments (**p < 0.01; ***p < 0.001 vs control). C. Effect of 
addition of various concentrations of bronchoalveolar lavage fluid (BALF) from a term newborn diluted in control medium 
(0.1% FBS) on in vitro alveolar epithelial wound healing (t = 24 hours). Bars represent mean wound closure + SEM (% of con-
trol) of triplicate experiments (*p < 0.05; **p < 0.01 vs. control). D. Effects of various concentrations of albumin and BALF 
(diluted 1:10) from a term newborn (total protein in the original BALF specimen was 1.7 mg/ml). Bars represent mean wound 
closure + SEM relative to control medium of triplicate experiments (***p < 0.001 vs. control).Respiratory Research 2009, 10:116 http://respiratory-research.com/content/10/1/116
Page 5 of 12
(page number not for citation purposes)
BALF has a concentration-dependent effect on wound 
closure
To evaluate the optimal dilution factor for BALF addition
to the model, and evaluate the concentration dependency
of the BALF effect on wound healing, BALF obtained from
a term newborn was added in various concentrations to
the model (Figure 1C). Addition of BALF to control
medium had a concentration-dependent stimulatory
effect on wound closure. For further experiments BALF
was diluted 1:10.
Albumin does not affect wound closure
Albumin is the most abundant protein in BALF and may
be increased in serious lung injury as a result of distortion
of the blood-air barrier. We evaluated the effect of addi-
tion of albumin to control medium on wound closure in
order to determine whether this would affect our model
(Figure 1D). Albumin did not significantly affect wound
closure, while wound closure was significantly enhanced
by addition of BALF, which contained less protein than
the highest albumin concentration used in the experi-
ment.
BALF characteristics and wound healing
74 BALF specimens were collected from 45 ventilated pre-
term infants. There was no significant difference in total
protein or wound closure between different postnatal
days when all patients were considered (not shown). No
significant differences in gestational age or birth weight
were present between the different patient groups (Table
1). Patients with chorioamnionitis had significantly
increased BALF total protein at day 7 when compared to
patients without chorioamnionitis. No other differences
in total protein were observed at any postnatal day.
Wound closure correlated significantly with BALF total
protein content (R2 = 0.44; p < 0.001) and wound closure
data are corrected for total BALF protein content in further
analyses. Neither wound closure nor BALF total protein
correlated with either gestational age or birth weight.
There was a close correlation between wound closure at t
= 6 and t = 24 (R2 = 0.80; p < 0.001), yet the majority of
the effect was reached within 6 hours after wound induc-
tion. Further analyses were performed only at t = 6.
To evaluate the effects of chorioamnionitis and antenatal
steroids, the capacity of BALF to stimulate alveolar epithe-
lial repair in vitro was compared between infants with and
without chorioamnionitis and infants that had and had
not received antenatal steroids.
Chorioamnionitis decreases wound healing capacity of 
BALF
BALF obtained from infants with histological chorioamni-
onitis demonstrated a significantly decreased capacity to
stimulate in vitro wound healing when compared to BALF
from infants without histological chorioamnionitis at day
Table 1: Patient characteristics. 
Wound healing experimental group Chorio
(n = 7)
No chorio
(n = 30)
Steroids
(n = 35)
No steroids
(n = 10)
Gestational age (weeks) (median (IQR)) 26.9 (25.6-28.7) 28.6 (27.0-39.3) 28.6 (26.9-29.4) 27.5 (26.2-29.7)
Birth weight (grams) (mean ± SD) 1027 ± 246 1069 ± 221 1091 ± 223 1028 ± 268
BALF total protein day 0/1 (mg/ml) (mean ± SD) 0.75 ± 0.49
(n = 7)
0.76 ± 0.47
(n = 28)
0.82 ± 0.57
(n = 32)
0.62 ± 0.46
(n = 9)
BALF total protein day 3/4 (mg/ml) (mean ± SD) 1.47 ± 2.38
(n = 5)
1.25 ± 1.34
(n = 14)
1.09 ± 1.22
(n = 19)
3.21 ± 3.53
(n = 2)
BALF total protein day 7 (mg/ml) (mean ± SD) 0.84 ± 0.39*
(n = 3)
0.44 ± 0.18
(n = 7)
0.51 ± 0.28
(n = 9)
0.95 ± 0.03
(n = 2)
Total population Chorio
(n = 8)
No chorio
(n = 37)
Steroids
(n = 51)
No steroids
(n = 11)
Gestational age (weeks) (median (IQR)) 26.5 (25.7-28.4) 28.4 (26.8-29.4) 28.6 (26.9-29.4) 27.6 (26.3-29.7)
Birth weight (grams)
(mean ± SD)
1014 ± 231 1045 ± 228 1079 ± 236 1045 ± 260
General characteristics of different patient groups included in the cell culture experiments and the total population (including VEGF and KGF 
quantification).
*p < 0.05 vs no chorioamnionitis day 7.
Abbreviations: chorio = chorioamnionitis; IQR = interquartile range; SD = standard deviation.Respiratory Research 2009, 10:116 http://respiratory-research.com/content/10/1/116
Page 6 of 12
(page number not for citation purposes)
0/1 (Figure 2A). No significant differences were observed
between infants with and without chorioamnionitis on
postnatal days 3/4 and 7.
Prenatal steroids stimulate wound healing capacity of 
BALF
BALF from infants exposed to antenatal steroids demon-
strated a significantly increased capacity to stimulate
wound healing at day 0/1 when compared to BALF from
non-exposed infants (Figure 2B). No significant differ-
ences were observed after day 0/1, although it should be
noted that at these time points the no steroids group com-
prised only two patients.
To further investigate the possible mechanisms of the
effects of chorioamnionitis and antenatal steroids on the
ability of BALF to repair alveolar epithelial injury in vitro,
we focused on BALF-induced apoptosis and possible roles
for KGF and VEGF, known modulators of lung develop-
ment and lung injury repair. KGF and VEGF were quanti-
fied in BALF and added to the model in various
concentrations.
BALF-induced apoptosis is not influenced by 
chorioamnionitis or antenatal steroids
To investigate whether the effects of chorioamnionitis and
antenatal steroids on day 0/1 could be explained by differ-
ential effects on BALF-induced apoptosis in A549 cells, we
quantified M30, a soluble marker of epithelial apoptosis,
in the cell culture supernatant at the end of the wound
healing experiment. No significant differences were
observed between culture supernatants of day 0/1 experi-
ments from infants with or without chorioamnionitis
(841 ± 338 vs. 1085 ± 316 U/L, p = 0.08; Figure 3A), and
from infants exposed or not exposed to antenatal betam-
ethasone (1028 ± 314 vs. 1041 ± 389 U/L, p = 0.42; Figure
3B).
Effects of chorioamnionitis and antenatal steroids on bronchoalveolar lavage fluid (BALF) wound healing capacity Figure 2
Effects of chorioamnionitis and antenatal steroids on bronchoalveolar lavage fluid (BALF) wound healing 
capacity. Effect of BALF obtained at different postnatal days from patients with and without chorioamnionitis (A), and from 
patients with and without antenatal steroid exposure (B) on in vitro alveolar epithelial wound healing. Bars represent mean 
wound closure +/- SEM (% above control/mg total protein in BALF) of triplicate experiments (*p < 0.05).Respiratory Research 2009, 10:116 http://respiratory-research.com/content/10/1/116
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Chorioamnionitis is associated with decreased KGF and 
less detectable VEGF in BALF
KGF and VEGF were quantified in 121 BALF specimens
from 62 patients, including all BALF specimens tested in
the in vitro wound healing experiments. KGF was detected
in 63%, 53%, 71% and 56% of BALF specimens obtained
on day 0, 1, 3/4 and 7, respectively. KGF in BALF corre-
lated positively with gestational age on day 0, but not
thereafter (R2 = 0.17, p < 0.05). VEGF was detected in
88%, 97%, 94% and 100% of BALF specimens obtained
on day 0, 1, 3/4 and 7, respectively.
KGF concentrations in BALF obtained on day 0 from
patients with chorioamnionitis were significantly lower
than those in BALF from patients without chorioamnioni-
tis (0 (0-5) vs. 11 (0-27), p < .05; Figure 4A). Furthermore,
no KGF was detectable in chorioamnionits-exposed
infants at day 7, while 75% of non-exposed infants had
detectable KGF (p < 0.05). BALF from infants with chori-
oamnionitis was significantly less likely to contain detect-
able levels of VEGF on day 0 when compared to BALF
from infants without chorioamnionitis (67% versus 95%,
p < 0.05). Absolute VEGF concentrations were not signifi-
cantly different between infants with or without chorio-
amnionitis on day 0 (9 (0-17) vs. 17 (7-29), p = 0.14), or
on any other day (Figure 4B).
Concentrations of both KGF and VEGF in BALF correlated
significantly with the ability of BALF to stimulate alveolar
epithelial repair in vitro albeit with low R2 values (R2 =
0.08, p < 0.05; and R2 = 0.10, p < 0.01, respectively). This
illustrates that small part of the decreased ability of BALF
obtained from patients with chorioamnionitis to stimu-
late alveolar epithelial repair may result from the
decreased availability of these growth factors. No signifi-
cant differences in BALF VEGF or KGF concentrations
were detected on any day between patients that had or
had not received antenatal steroids.
KGF, VEGF and in vitro wound healing
Remaining BALF was pooled for further experiments
aimed at evaluating the roles of KGF and VEGF in BALF on
wound repair. The pooled BALF contained 40 pg/ml
VEGF, but undetectable levels of KGF. In the absence of
BALF, VEGF stimulated alveolar epithelial repair, an effect
that was blocked by addition of sVEGFr1 (Figure 5A).
However, addition of the same concentrations of
sVEGFr1, VEGF, or a combination of both to BALF did not
significantly alter its effect on wound healing (Figure 5A).
To evaluate whether natural abundance of sVEGFr1 in
BALF could explain the inability to detect a VEGF-medi-
ated effect on BALF-induced alveolar epithelial wound
repair, we quantified sVEGFr1 in a subset of remaining
BALF samples (n = 10). sVEGFr1 was present in significant
amounts in all evaluated samples (median [range] = 5.39
[1.28; >10] ng/l).
Given the undetectable levels of KGF in the BALF pool, no
attempts to antagonise the effect of KGF in BALF were
made. Nevertheless, KGF was shown to have a concentra-
tion dependent stimulatory effect on wound healing (Fig-
ure 5B).
Discussion
We report the development and characterisation of a
translational in vivo/in vitro model for alveolar epithelial
repair. Wound repair was quantified after mechanical
wounding of a monolayer of A549 cells. FBS and BALF
stimulated alveolar epithelial wound healing in this
model in a concentration-dependent manner. Physiologi-
cal concentrations of albumin, the most abundant protein
in BALF, did not affect wound repair indicating that the
effect of BALF results from actions of specific mediators
rather than a general protein or dilutional effect. BALF
from patients with chorioamnionitis had a significantly
reduced capacity to induce alveolar epithelial wound
healing, while exposure to antenatal steroids was associ-
M30 detected in culture supernatant after day 0/1 wound  healing experiment according to chorioamnionitis or betame- thasone exposure Figure 3
M30 detected in culture supernatant after day 0/1 
wound healing experiment according to chorioamni-
onitis or betamethasone exposure. Bars represent mean 
wound closure + SEM per group. No significant differences 
between groups were present.Respiratory Research 2009, 10:116 http://respiratory-research.com/content/10/1/116
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ated with increased wound healing capacity of BALF
shortly after birth. These effects were not attributable to
alterations in BALF-induced apoptosis. BALF from
patients exposed to chorioamnionitis contained lower
levels of KGF and less detectable VEGF on postnatal day 0.
BALF wound healing capacity correlated with levels of
both of these and addition of these factors to our model
resulted in stimulation of alveolar epithelial repair. How-
ever, results from subsequent experiments suggest that, at
the concentrations present, their contribution to BALF-
induced wound repair is at best around 10%, although
significant effects could not be demonstrated.
Evaluation of epithelial wound healing in vitro is an estab-
lished model for epithelial repair after injury and has been
applied and characterised for many different epithelial
types, including the alveolar epithelium [8]. Many inves-
tigators have used primary cultures of alveolar type II cells
isolated from animal lungs in epithelial repair models
since A549 cells do not hold all characteristics of type II
cells and freshly isolated human type II cells are not read-
ily available [8,27,29]. Still, of all human cell-lines availa-
ble A549 cells share most characteristics with alveolar type
II cells and are most widely used in human in vitro models
of alveolar physiology. More importantly, in testing the
biological activity of human BALF, we refrained from
using animal-derived type II cells because of concerns
regarding loss or modulation of biological signal due to
species difference, in accordance with previous reports
[9,10].
We are aware of only two earlier reports evaluating the
effect of human lung-derived fluid on alveolar epithelial
repair in vitro [9,10]. Perkins et al. recently showed that in
patients ventilated for acute respiratory distress syndrome
(ARDS), treatment with salbutamol, a β2-agonist, signifi-
Keratinocyte growth factor (KGF) and vascular endothelial growth factor (VEGF) levels in bronchoalveolar lavage fluid (BALF) Figure 4
Keratinocyte growth factor (KGF) and vascular endothelial growth factor (VEGF) levels in bronchoalveolar 
lavage fluid (BALF). KGF (A) and VEGF (B) levels in bronchoalveolar lavage fluid (BALF) obtained at different postnatal days 
from patients with and without chorioamnionitis. Points represent individual BALF growth factor concentrations, horizontal 
lines represent medians (*p < 0.05).Respiratory Research 2009, 10:116 http://respiratory-research.com/content/10/1/116
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cantly increased the ability of BALF to stimulate wound
healing in A549-cells [10]. Interestingly, BALF derived
from salbutamol-treated patients also contained higher
levels of VEGF, although the authors show evidence that
in their study interleukin-1β (IL-1β) and not VEGF was
the main contributor to epithelial repair [10]. In an earlier
report, pulmonary edema fluid from ventilated adult
patients with acute lung injury (ALI)/ARDS enhanced
wound repair when compared to plasma or edema fluid
from ventilated patients with hydrostatic edema [9]. Addi-
tional experiments suggested that IL-1β accounted for part
of this effect, although edema fluid IL-1β concentrations
were not reported. IL-1β was not evaluated in our model
since BALF levels were increased rather than decreased
after chorioamnionitis in our cohort (unpublished obser-
vations), arguing against its contribution to the decreased
wound healing ability of BALF. IL-1 receptor antagonist
(IL-1ra) induced by BALF in A549 cells or present in the
alveolar space may further modulate the effects of IL-1β,
complicating assessment of its contribution to our find-
ings. Considering the inflammatory nature of both ALI/
ARDS and chorioamnionitis, one might expect that these
conditions have similar effects on wound repair. How-
ever, chorioamnionitis was associated with decreased
wound healing in our model whereas BALF from ALI/
ARDS patients increased wound repair [9]. Total protein
concentrations in edema fluid from ALI/ARDS patients
were also significantly higher [9], possibly explaining part
of its increased wound healing potential. Furthermore
age-related differences, differences in specimen used
(BALF versus edema fluid) and growth factor patterns may
partly account for differences.
A unique aspect of our study is the evaluation of the dif-
ferential effect of BALF collected consecutively within dis-
tinct patient groups. We observed clear effects of the
antenatal antecedents studied on wound healing capacity
of BALF early after birth, whereas no significant effects
were present later on. Thus, the effects of modulators of
wound healing present in BALF on epithelial repair
appear to vary over time. Multiple studies have shown
that short term exposure to injury may induce important
and sustained lung damage [30,31]. Therefore, modula-
tion of lung injury repair by antenatal events seen in our
study is likely to be of clinical importance, even though
the effects are only observed shortly after birth. A larger
time window between the antecedent and its effect, and
possible interference of other factors influencing repair
capacity may explain disappearance of the association
over time [32].
The decreased capacity of BALF from patients previously
exposed to chorioamnionitis to restore epithelial integrity
provides a novel link between antenatal inflammation
and adverse lung development [3,4,33]. Our model is
unique in comparing biological activity of human BALF
between patients with and without chorioamnionitis. The
data suggest that prenatal exposure to inflammation
results in BALF that is less efficient in repairing lung
injury. This may explain why chorioamnionitis alone may
not predispose to adverse lung development, while addi-
tional exposure to postnatal injurious factors such as
mechanical ventilation and sepsis highly augments its
association with chronic lung disease [11,12]. Experimen-
tal chorioamnionitis in preterm sheep increases the
inflammatory response to postnatal mechanical ventila-
tion, suggesting that inflammatory factors play a role [34].
Vascular endothelial growth factor (VEGF) and keratinocyte  growth factor (KGF) and effects on alveolar epithelial wound  repair Figure 5
Vascular endothelial growth factor (VEGF) and 
keratinocyte growth factor (KGF) effects on alveolar 
epithelial wound repair. Effect of addition of different 
combinations of bronchoalveolar lavage fluid (BALF), VEGF 
(10 pg/ml), and soluble VEGF-receptor 1 (sVEGFr1; 6 ng/ml) 
(A), or various concentrations of KGF (B) on in vitro alveolar 
epithelial wound healing. Bars represent mean wound closure 
+ SEM (% of control) of triplicate experiments (*p < 0.05, and 
**p < 0.01 vs control). No significant differences are present 
between BALF alone and BALF with any addition. Significant 
differences between VEGF, and both sVEGFr1 and VEGF + 
sVEGFr1 are present (both p < .05).Respiratory Research 2009, 10:116 http://respiratory-research.com/content/10/1/116
Page 10 of 12
(page number not for citation purposes)
Paradoxically, classic inflammatory cytokines known to
be upregulated in chorioamnionitis have previously been
shown to stimulate wound repair [8,9]. The finding of
decreased epithelial repair after chorioamnionitis in our
model suggests an additional role for other modulators.
Although our initial experiments suggest that decreased
levels of VEGF and KGF after chorioamnionitis may
explain part of the decreased ability of BALF to induce
alveolar epithelial repair, a definite contribution of nei-
ther factor could be established. We were able confirm
earlier reports of stimulatory effects of VEGF and KGF on
in vitro alveolar epithelial wound healing [27-29], and
decreased availability of VEGF after chorioamnionitis [7].
Moreover, both KGF and VEGF levels in BALF are linked
to development of BPD in previous reports [16-18,26], as
well as in our sample [15]. A considerable amount of ani-
mal experimental data further supports a pivotal role of
both factors in lung development and repair [19-
25,27,28,35]. Thus, the early decrease in BALF levels of
KGF and VEGF is likely to contribute to adverse lung
development seen after chorioamnionitis, although our
experiments suggest that their effects are primarily exerted
through mechanisms other than BALF-induced alveolar
epithelial repair. The overall low levels of VEGF and KGF
as compared to adult studies may reflect developmental
regulation as well as differences in BAL technique (e.g.
non-bronchoscopic versus bronchoscopic). Furthermore,
the potential role of the apparent abundance of sVEGFr1
in the alveolar space in decreasing VEGF bioavailability
warrants further investigation [36].
Although antenatal steroids reduce RDS incidence,
enhance structural maturity of the lung and improve lung
function [1,2,37], BPD incidence seems unaffected [1].
However, when only studies using betamethasone are
considered, BPD is significantly reduced [1]. By demon-
strating an association between antenatal betamethasone
and enhanced alveolar epithelial repair, our data provide
a potential link between betamethasone exposure and
improved lung development.
An earlier study found no effect of corticosteroids on air-
way epithelial repair [38], while another showed dexame-
thasone to inhibit wound repair initially, while inducing
extended subsequent wound-healing potential in bron-
chial epithelial cells [39]. Thus, the direct effect induced
by corticosteriods seems to differ from the longer term
changes that affect the cellular response to injury. In
sheep, maternal betamethasone acetate administration
results in peak fetal plasma concentrations after 3 hours,
dropping below the detection limit within 8 hours [40].
Since infants in our study were exposed to maternal ster-
oids hours to weeks before birth, indirect mechanisms
most likely explain the increased BALF wound healing
capacity seen in our model. We were unable to detect bet-
amethasone effects on BALF-induced apoptosis, and
VEGF or KGF levels, suggesting that other factors play a
role in this process.
Our model obviously is a simplified representation of the
in vivo situation, since the alveolar space consist of a com-
bination of different cell types. Communication between
these cells cannot be investigated in our current model.
Still we feel this model is an important first step in the
identification of risk factors and protective factors in lung
injury repair and of the underlying mechanisms at a
molecular level. Larger patient groups are needed to fur-
ther evaluate possible other modulating factors, such as
oxygen exposure, mechanical ventilation characteristics
and the combined effects of chorioamnionitis and ante-
natal steroids [3,41].
Conclusion
A translational in vivo/in vitro model for alveolar epithelial
repair using BALF as a reflection of the in vivo pulmonary
environment, was characterised and applied. The evalua-
tion of alveolar epithelial repair capacity of BALF serially
collected in distinct patient groups provides a unique
means by which biological activity of human specimens
can be linked to clinical parameters over time. BALF
obtained shortly after birth from preterm infants exposed
to chorioamnionitis had a significantly decreased ability
to restore alveolar epithelial integrity in vitro, providing a
biological link between chorioamnionitis and adverse
lung development. Our data suggest that the contribution
of VEGF and KGF in BALF to this effect is probably small,
although their decrease after chorioamnionitis may well
modulate the susceptibility for adverse lung development.
Conversely, prenatal steroid administration was shown to
significantly increase wound-healing capacity of BALF in
preterm infants. Additional research is needed to study
the underlying mechanisms of modulation of alveolar
epithelial repair by chorioamnionitis and antenatal ster-
oids. Further evaluation of biological activity of human
specimens in translational models like the one presented
here carries great potential to study mechanisms underly-
ing disease associations.
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